Which brands do you think in India have similar pull or affinity led growth.
Posts in category Value Pickr
Great Eastern Shipping (GE Shipping) – Possible Sleeper? (07-04-2024)
Can anyone pls advise why the tax rate is less during the past few years (less than 5% for the last many qtrs) despite the profit has grown. thank you.
AllCargo Logistics – Are good time ahead? (07-04-2024)
Based on this, do you think there is any arbitrage situation possible?
CRAFTSMAN AUTOMATION – Diversified Light Engineering Company (07-04-2024)
Craftsman Automation Ltd. is a versatile engineering company that caters to the automotive and industrial OEMs. With a strong presence in various segments, the automotive sector contributes to 73% of their total revenue.
Craftsman Automation holds the title of being the largest player in India when it comes to machining cylinder blocks and cylinder heads in the M&HCV and construction equipment industries.
Their product lines are neatly categorized into three divisions: automotive power-train, automotive aluminium, and industrial & engineering. The company is headquartered in Coimbatore, Tamil Nadu, and operates 12 plants across India.
Product Offerings:
Automotive – Powertrain and Others: The range of products available encompasses various engine components, including cylinder blocks, cylinder heads, camshafts, transmission parts, gearbox housings, turbochargers, and bearing caps.
Automotive – Aluminium Products: The offerings consist of crankcases and cylinder blocks for two-wheelers, engine and structural parts for passenger vehicles, and gearbox housings for heavy commercial vehicles.
Industrial and Engineering: This segment can be further divided into two sub-segments. The first sub-segment focuses on storage solutions, providing comprehensive options for both conventional and automated storage systems. The second sub-segment specializes in high-end precision products, manufacturing aluminum products and offering services such as sub-assembly, material handling equipment, metal cutting, non-metal applications (such as washing and leak testing solutions), as well as tool room, mold base, and sheet metal capabilities.
Craftsman Automation Limited Advantages :
- An engineering company with a wide range of capabilities in manufacturing and a commitment to delivering complete solutions while producing top-notch, complex products, components, and parts.
- Impressive internal capabilities for both process and product design.
- Strong, enduring partnerships with key OEMs both locally and internationally.
- Wide-reaching manufacturing presence, with facilities strategically positioned to adjust capacity and product variety as needed.
- Seasoned management team backed by a dedicated and talented workforce.
- Strong financial track record.
In Current dip stock seems to be undervalued now. (not a recommendation).
4000-4200 seems to be buying area
Craftsman Automation is currently being traded at an appealing valuation, boasting a 3.6 Enterprise value to Capital Employed ratio and a PEG (Price/Earnings to Growth) ratio of 0.7. These figures strongly suggest that the stock is undervalued when compared to its historical valuations.
Furthermore, one of the company’s notable strengths lies in its high institutional holdings, which currently stand at 29.74%. This signifies that institutional investors, who possess superior resources and capabilities to analyze company fundamentals, have demonstrated their confidence in Craftsman Automation.
Deepak Fertilizers and Petrochemicals (07-04-2024)
Thanks for sharing good article on the company!!!
TVS Supply Chain Solutions- A Business Analysis (07-04-2024)
Don’t they have the first mover advantage and high entry barrier as the moat? I believe there will be a shift towards more organised players in the coming years, and this stock will look attractive around 150-160 with ample margin of safety. Alternative thesis are welcome.
My portfolio updates and investment journey (07-04-2024)
@anmol_satyam Tejas i was mesmerized by order book, however margins seems to be difficult. I used this to concentrate my portfolio on my high conviction bets. Frog cellsat- i dont want to be in sme at this market levels. I rather enter micro cap and sme when there is drastic fall.
Semiconductor world – CPU/GPU Wars (07-04-2024)
As far as services is concerned:
There is extreme shortage of experienced professionals in this space. Few big companies have not really contributed as much as they could in this area. Why? Large MNCs have these processes that abstract out the engineering knowhow to do the job to a great extent. So we are seeing professionals with 10-15 years experience doing Silicon Validation in top companies with close to nil understanding of electronics/electrical fundamentals.
I am also seeing services companies trying to level up their Silicon game. I have seen one of the well known companies fail to deliver on their commitments too. This is not an easy area to enter. Requires engineering knowledge/skills. The aquisition makes sense (in a way… looking at it from far off).
Great articles to read on the web (07-04-2024)
Antibiotic-resistant bacterial infections cause more than a million deaths worldwide every year. That number is expected to rise over the next decades unless new antibiotics can be developed.
Many antibiotics work by binding to and shutting down bacterial ribosomes. These are the molecular machines that build the proteins cells need to function. Over the last several decades, bacteria have evolved various mechanisms to prevent their ribosomes from being blocked by antibiotics. Often, genetic variants lead to changes in the chemical makeup of the ribosomes that prevent the antibiotics from binding.
A research team led by Dr. Andrew Myers from Harvard University, working with Dr. Yury Polikanov from the University of Illinois at Chicago, has been studying ways to tweak antibiotics to beat resistance. In a new study, funded in part by NIH, they examined an older class of antibiotic called lincosamides. Their results were published on February 16, 2024, in Science.
Lincosamide antibiotics are based on molecules found in nature, so are called semi-synthetic drugs. Using knowledge of the molecular structure of these antibiotics and how they bind to bacterial ribosomes, the team developed a fully synthetic compound called cresomycin. They chose its building blocks so that it would form the exact shape needed to latch tightly onto ribosomes.
The team found that cresomycin worked in both gram-positive and gram-negative bacteria. The latter are especially hard to treat with existing antibiotics. It also worked in strains resistant to other lincosamide antibiotics.
Using x-ray crystallography, the team explored how cresomycin overcomes the two most common resistance mechanisms that defeat other antibiotics. They obtained crystal structures of cresomycin in complex with two ribosomes that had been modified by different antimicrobial resistance genes. The structures revealed the tiny adjustments between the new antibiotic and the ribosomes that enabled tight binding.
The researchers next tested cresomycin in mice with antibiotic-resistant Staphylococcus aureus infections. When treated with the new drug, 10 of 10 mice survived for seven days after infection with a lethal dose of antibiotic-resistant bacteria. By contrast, 9 of 10 mice that received no drug died within two days of infection. Cresomycin also suppressed bacterial growth in mice infected with antibiotic-resistant Escherichia coli and Pseudomonas aeruginosa.
When tested in cultured human cells, cresomycin didn’t cause notable damage. The researchers are now working with a nonprofit biotechnology accelerator to move the drug closer to clinical trials.
“We don’t yet know whether cresomycin and drugs like it are safe and effective in humans. But our results show significantly improved inhibitory activity against a long list of pathogenic bacterial strains that kill more than a million people every year, compared with clinically approved antibiotics,” says Myers.
My portfolio updates and investment journey (07-04-2024)
I have joined Korman Capital.